MDT excellence in HSPC care

Multidisciplinary excellence in HSPC care

What role do multidisciplinary teams (MDTs) play in treatment decision-making for hormone-sensitive prostate cancer (HSPC), and how can a more holistic approach improve patient outcomes?

These questions were explored in an expert discussion chaired by Bertrand Tombal (Belgium), with Andrew Armstrong, Alicia Morgans, and Daniel George (USA), which covered:

• Effective diagnosis and management of HSPC and biochemical recurrence (BCR)
• Practical tips for MDT involvement in treatment decision-making for both non-metastatic (nm) and metastatic (m) HSPC
• Patient-centric approaches to care and communication throughout the patient journey

Access the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information (PI) for enzalutamide. Adverse event reporting can be found at the bottom of the page.

Biochemical recurrence: Practical tips for the clinic

What are key considerations in the diagnosis and treatment of BCR in nmHSPC? Andrew Armstrong (Duke Cancer Institute, Durham, North Carolina, USA) discusses guidelines, risk, and benefits, and how a multidisciplinary approach fits into BCR management in clinical practice. View transcript.

Optimizing care in multidisciplinary teams

What are the key strategies and considerations for multidisciplinary prostate cancer care? Alicia Morgans (Harvard Medical School, Boston, Massachusetts, USA) provides practical guidance on holistic approaches and outlines the roles of key multidisciplinary team members across localized and locally advanced nmHSPC, as well as BCR and mHSPC. View transcript.

A patient-centric approach to care

How do we ensure a patient-centric approach to care in people with nmHSPC, BCR, or mHSPC? Daniel George (Duke Cancer Institute, Durham, North Carolina, USA) explains his approach to patient communication, how to manage adverse events, and how to use patient-reported outcomes to put the patient at the forefront of care. View transcript.

Expert Q&A discussion

What practical strategies may help improve MDT utilization in real-world practice? Bertrand Tombal (Université catholique de Louvain, Brussels, Belgium) leads an expert panel discussion drawing on the panel’s collective experience of MDT working. Topics include practical “must-do” MDT steps to avoid under- and overtreatment, how to ensure each specialist is meaningfully involved in decision-making, and which information to prioritize in patient conversations. View transcript.

Meet the experts

Bertrand Tombal, MD, PhD

Bertrand Tombal is Full Professor of Urology at the Université catholique de Louvain (UCL) and Chairman of the Division of Urology at the Cliniques universitaires Saint-Luc in Brussels, Belgium. He is interested in urinary oncology from scientific and medical perspectives, particularly prostate and bladder cancer. Tombal’s primary focus in the medical sector is the treatment of advanced prostate cancer, mainly through hormone therapy and the development of novel biologic agents.

Disclosures: Investigator and paid advisor for Amgen, Astellas, Bayer, Ferring, Janssen, Myovant, Pfizer, and Sanofi.

Andrew Armstrong, MD, ScM, FACP

Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. As a clinical and translational investigator, he specializes in experimental therapeutics for advanced genitourinary malignancies, with an emphasis on prostate and kidney cancer, and the investigation of biomarkers of response and benefit both in the laboratory and in the clinic.

Disclosures: Research and/or consulting/advising fees from Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, DOD, Exelixis, Forma, GoodRx, Janssen, Medscape, Merck, MJH, Myovant, NIH/NCI, Novartis, Pathos, PCF/Movember, Pfizer, Telix, and Z Alpha.

Alicia Morgans, MD, MPH

Alicia Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist, and Director of the Adult Survivorship Program at Dana-Farber Cancer Institute. She has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision-making. Her research interests include complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications, and she leads multiple therapeutic and quality-of-life focused clinical trials.

Disclosures: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Exelixis, Johnson & Johnson, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Sumitomo Pharma, Inc., Telix, and Tolmar.

Daniel George, MD

Daniel George is an Eleanor Easley Distinguished Professor in the School of Medicine, Professor of Medicine, Professor in Urology, Professor in Surgery, and Member of the Duke Cancer Institute at Duke University, Durham, North Carolina, USA. He specializes in the comprehensive care of people with urologic cancers, with a particular focus on prostate, kidney, bladder, and testicular cancer. His research interests also include the exploration of lifestyle interventions and support mechanisms to improve overall experience for patients.

Disclosures: Grant/research/clinical trial support from Astellas, AstraZeneca, Bristol Myers Squibb, CORVUS, Exelixis, Janssen, Merck Sharp & Dohme, Novartis, and Pfizer; consultant/advisory boards from ABRX, Astellas, AstraZeneca, Bayer, Eisai, Exelixis, Janssen Pharmaceuticals, Merck Sharp & Dohme, MJH Life Sciences, Novartis, Pfizer, and Sumitovant Biopharma; other financial interests include American Association for Cancer Research, Bayer, Exelixis, IdeoLogy Health, Millennium Medical Publishing – Clinical Advances in Hematology & Oncology, MJH Life Sciences, Pfizer, UroGPO, and UroToday (Digital Science Press).

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit–risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to Astellas. Please refer to the SmPC or PI approved in your local country for further information.